Investigating Lipid Levels in Children with Obesity-Related Asthma

E
Erick Forno

Primary Investigator

Recruiting
8 years - 21 years
All
Phase N/A
100 participants needed
1 Location

Brief description of study

The purpose of this research is to learn more about how the levels of different lipids affect kids with asthma and obesity. We're especially interested in how it affects kids with certain characteristics or types of asthma. In the long term, we hope this will help us understand if taking algae oil (high in certain types of lipids) might help some kids with asthma control their symptoms and reduce inflammation in their lungs.

Detailed description of study

  • We will test the associations between plasma lipidomic profiles.
  • Participants will complete up to 2 study visits over 3 months
  • Study visits will take place at Riley Hospital for Children in the Children's Clinical Research Center (CCRC) and/or the Pulmonary Function Testing (PFT) lab.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Asthma, Riley
  • Age: 8 years - 21 years
  • Gender: All

Inclusion criteria:
•    Age ≥8 to <21 years (i.e., 8.00-20.99 years)
•    Diagnosis of persistent asthma (defined as prescription of ICS for ≥6 months of the past year)
•    At least 1 severe exacerbation in the past year (defined per ATS/ERS criteria as a hospitalization, ED visit, or ≥3 days of systemic steroids for asthma)
•    Stable ICS dose for ≥4 weeks prior to enrollment
•    Ability to perform high-quality spirometry per ATS guidelines
•    BMI ≥5 to <85th percentile (HWA) or ≥85th percentile (ORA)

Exclusion criteria:
•    Asthma that requires chronic systemic steroids.
•    Any of the following in the past 4 weeks**:
o    Systemic or nasal steroids
o    Acute lower respiratory illness
o    Acute sinusitis requiring antibiotics
o    Reported smoking, vaping, or e-cigarette use
o    Concurrent enrollment in any interventional studies
o    DHA, -3, or other essential fatty acid dietary supplements
•    Other chronic respiratory diseases (e.g., cystic fibrosis, bronchopulmonary dysplasia).
•    Significant comorbidities that may affect participant safety or interfere with study outcomes.
•    Low BMI (< 5th percentile).

Updated on 23 Jun 2025. Study ID: PPUL-IIR-LORA, 26169

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the Study Team